Extracellular	O
signal-regulated	O
protein	O
kinase	O
(	O
ERK	O
)	O
-dependent	O
and	O
ERK-independent	O
pathways	O
target	O
STAT3	B-protein
on	O
serine-727	O
in	O
human	O
neutrophils	O
stimulated	O
by	O
chemotactic	B-protein
factors	I-protein
and	O
cytokines	B-protein
.	O

STAT3	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	B-protein
or	O
growth	B-protein
factors	I-protein
.	O

Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	B-protein
serine	I-protein
kinases	I-protein
also	O
phosphorylate	O
STAT3	B-protein
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O

Here	O
we	O
demonstrate	O
,	O
with	O
a	O
site-specific	O
antibody	O
,	O
that	O
STAT3	B-protein
is	O
phosphorylated	O
on	O
Ser-727	O
in	O
human	B-cell_type
neutrophils	I-cell_type
stimulated	O
with	O
chemotactic	B-protein
factors	I-protein
(	O
N-formyl-methionyl-leucyl-phenylalanine	O
and	O
complement	O
C5a	O
)	O
,	O
cytokines	B-protein
[	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
]	O
,	O
or	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
activator	O
(	O
PMA	O
)	O
.	O

(	O
2-Amino-3'-methoxyphenyl	O
)	O
oxanaphthalen-4-one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal-regulated	B-protein
protein	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B-protein
induced	O
by	O
chemotactic	B-protein
factors	I-protein
or	O
PMA	O
.	O

The	O
drug	O
was	O
less	O
effective	O
on	O
cytokines	B-protein
:	O
it	O
virtually	O
abolished	O
the	O
response	O
to	O
GM-CSF	B-protein
that	O
occurred	O
5	O
min	O
after	O
stimulation	O
but	O
only	O
partly	O
decreased	O
those	O
at	O
15-30	O
min	O
and	O
did	O
not	O
appreciably	O
alter	O
responses	O
to	O
G-CSF	B-protein
regardless	O
of	O
incubation	O
time	O
.	O

1-	O
(	O
5-Isoquinolinylsulphonyl	O
)	O
-2-methylpiperazine	O
dihydrochloride	O
(	O
H7	O
)	O
,	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	B-protein
serine	I-protein
kinase	I-protein
,	O
and	O
4-	O
(	O
4-fluorophenyl	O
)	O
-2-	O
(	O
4-methylsulphinylphenyl	O
)	O
-5-	O
(	O
4-pyridyl	O
)	O
1H-imidazole	O
(	O
SB	O
203580	O
)	O
,	O
an	O
inhibitor	O
of	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O

We	O
propose	O
that	O
neutrophils	B-cell_type
use	O
both	O
ERK-dependent	O
and	O
ERK-independent	O
pathways	O
to	O
phosphorylate	O
Ser-727	O
on	O
STAT3	B-protein
.	O

The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	B-protein
-activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	B-protein
kinase	I-protein
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	B-protein
.	O

Biochem	NULL
.	NULL

J	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
341	NULL
,	NULL
691-696	NULL
(	NULL
Printed	NULL
in	NULL
Great	NULL
Britain	NULL
)	NULL
691	NULL
Extracellular	NULL
signal-regulated	NULL
protein	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
-dependent	NULL
and	NULL
ERK-independent	NULL
pathways	NULL
target	NULL
STAT3	NULL
on	NULL
serine-727	NULL
in	NULL
human	NULL
neutrophils	NULL
stimulated	NULL
by	NULL
chemotactic	NULL
factors	NULL
and	NULL
cytokines	NULL
Mitsuyuki	NULL
KUROKI	NULL
and	NULL
Joseph	NULL
T.	NULL
O'FLAHERTY	NULL
!	NULL

Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
Section	NULL
on	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Wake	NULL
Forest	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Medical	NULL
Center	NULL
Boulevard	NULL
,	NULL
Winston-Salem	NULL
,	NULL
NC	NULL
27157	NULL
,	NULL
U.S.A.	NULL
STAT3	NULL
(	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
3	NULL
)	NULL
is	NULL
a	NULL
latent	NULL
transcription	NULL
factor	NULL
that	NULL
is	NULL
activated	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
Tyr-705	NULL
)	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
cytokines	NULL
or	NULL
growth	NULL
factors	NULL
.	NULL

Recent	NULL
studies	NULL
suggest	NULL
that	NULL
one	NULL
or	NULL
more	NULL
cyto-plasmic	NULL
serine	NULL
kinases	NULL
also	NULL
phosphorylate	NULL
STAT3	NULL
and	NULL
are	NULL
necessary	NULL
for	NULL
maximal	NULL
gene	NULL
activation	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
,	NULL
with	NULL
a	NULL
site-specific	NULL
antibody	NULL
,	NULL
that	NULL
STAT3	NULL
is	NULL
phosphorylated	NULL
on	NULL
Ser-727	NULL
in	NULL
human	NULL
neutrophils	NULL
stimulated	NULL
with	NULL
chemotactic	NULL
factors	NULL
(	NULL
N-formyl-methionyl-leucyl-phenylalanine	NULL
and	NULL
complement	NULL
CSa	NULL
)	NULL
,	NULL
cytokines	NULL
[	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
]	NULL
,	NULL
or	NULL
a	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
(	NULL
PMA	NULL
)	NULL
.	NULL

(	NULL
2-Amino-3	NULL
``	NULL
-methoxyphenyl	NULL
)	NULL
oxanaphthalen-4-one	NULL
(	NULL
PD	NULL
98059	NULL
)	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
extracellular	NULL
signal-regulated	NULL
protein	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
activation	NULL
,	NULL
blocked	NULL
the	NULL
serine	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
induced	NULL
by	NULL
chemotactic	NULL
factors	NULL
or	NULL
PMA	NULL
.	NULL

The	NULL
drug	NULL
was	NULL
less	NULL
effective	NULL
on	NULL
cytokines	NULL
:	NULL
it	NULL
virtually	NULL
abolished	NULL
the	NULL
response	NULL
to	NULL
GM-	NULL
CSF	NULL
that	NULL
occurred	NULL
5	NULL
min	NULL
after	NULL
stimulation	NULL
but	NULL
only	NULL
partly	NULL
decreased	NULL
those	NULL
at	NULL
15-30	NULL
min	NULL
and	NULL
did	NULL
not	NULL
appreciably	NULL
alter	NULL
responses	NULL
to	NULL
G-CSF	NULL
regardless	NULL
of	NULL
incubation	NULL
time	NULL
.	NULL

1-	NULL
(	NULL
5-Isoquinolinylsulphonyl	NULL
)	NULL
-2-methylpiperazine	NULL
dihydrochloride	NULL
(	NULL
H7	NULL
)	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
a	NULL
putative	NULL
STAT3	NULL
serine	NULL
kinase	NULL
,	NULL
and	NULL
4-	NULL
(	NULL
4-fluorophenyl	NULL
)	NULL
-2-	NULL
(	NULL
4-methylsulphinylphenyl	NULL
)	NULL
-5-	NULL
(	NULL
4-pyridyl	NULL
)	NULL
1H-imidazole	NULL
(	NULL
SB	NULL
203580	NULL
)	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
(	NULL
MAP	NULL
)	NULL
kinase	NULL
,	NULL
did	NULL
not	NULL
dampen	NULL
any	NULL
of	NULL
these	NULL
serine	NULL
phosphorylation	NULL
responses	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
neutrophils	NULL
use	NULL
both	NULL
ERK-dependent	NULL
and	NULL
ERK-independent	NULL
pathways	NULL
to	NULL
phosphorylate	NULL
Ser-727	NULL
on	NULL
STAT3	NULL
.	NULL

The	NULL
former	NULL
pathway	NULL
is	NULL
recruited	NULL
by	NULL
all	NULL
ERK-activating	NULL
stimuli	NULL
,	NULL
whereas	NULL
the	NULL
latter	NULL
pathway	NULL
uses	NULL
an	NULL
undefined	NULL
serine	NULL
kinase	NULL
and	NULL
is	NULL
recruited	NULL
selectively	NULL
by	NULL
cytokines	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
serine	NULL
kinase	NULL
,	NULL
transcription	NULL
factor	NULL
,	NULL
signal	NULL
trans-duction	NULL
.	NULL

INTRODUCTION	NULL
Signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
(	NULL
STATs	NULL
)	NULL
were	NULL
first	NULL
identified	NULL
as	NULL
interferon-responsive	NULL
transcription	NULL
factors	NULL
.	NULL

So	NULL
far	NULL
,	NULL
seven	NULL
different	NULL
STATs	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
mammals	NULL
and	NULL
shown	NULL
to	NULL
participate	NULL
in	NULL
the	NULL
signalling	NULL
initiated	NULL
by	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cytokines	NULL
and	NULL
growth	NULL
factors	NULL
[	NULL
1-3	NULL
]	NULL
.	NULL

These	NULL
transcription	NULL
factors	NULL
contain	NULL
a	NULL
Sre	NULL
homology	NULL
2	NULL
domain	NULL
and	NULL
a	NULL
C-terminal	NULL
tyrosine	NULL
phosphorylation	NULL
site	NULL
.	NULL

STAT	NULL
proteins	NULL
exist	NULL
as	NULL
inactive	NULL
monomers	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

After	NULL
phosphorylation	NULL
on	NULL
tyrosine	NULL
,	NULL
they	NULL
dimerize	NULL
,	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
bind	NULL
specific	NULL
DNA	NULL
promoter	NULL
sequences	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
found	NULL
that	NULL
several	NULL
STATs	NULL
,	NULL
including	NULL
STAT3	NULL
,	NULL
are	NULL
also	NULL
phosphorylated	NULL
on	NULL
serine	NULL
[	NULL
4-13	NULL
]	NULL
.	NULL

Serine	NULL
phosphorylation	NULL
is	NULL
not	NULL
an	NULL
absolute	NULL
requirement	NULL
for	NULL
transcriptional	NULL
activation	NULL
but	NULL
might	NULL
be	NULL
an	NULL
important	NULL
modulating	NULL
signal	NULL
[	NULL
4	NULL
]	NULL
.	NULL

The	NULL
site	NULL
of	NULL
phosphorylation	NULL
(	NULL
Ser-727	NULL
)	NULL
is	NULL
located	NULL
within	NULL
a	NULL
consensus	NULL
sequence	NULL
(	NULL
Pro-Met-Ser-Pro	NULL
)	NULL
for	NULL
members	NULL
of	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
(	NULL
MAP	NULL
)	NULL
kinase	NULL
family	NULL
.	NULL

However	NULL
,	NULL
the	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
responsible	NULL
for	NULL
this	NULL
phosphorylation	NULL
as	NULL
well	NULL
as	NULL
the	NULL
precise	NULL
function	NULL
of	NULL
these	NULL
events	NULL
are	NULL
the	NULL
subject	NULL
of	NULL
controversy	NULL
.	NULL

Chemotactic	NULL
factors	NULL
,	NULL
e.g	NULL
.	NULL

N-formyl-methionyl-leucyl-phenyl-alanine	NULL
(	NULL
FMLP	NULL
)	NULL
and	NULL
complement	NULL
CSa	NULL
,	NULL
stimulate	NULL
human	NULL
neutrophil	NULL
migration	NULL
,	NULL
phagocytosis	NULL
,	NULL
granule	NULL
enzyme	NULL
release	NULL
and	NULL
super-oxide	NULL
production	NULL
[	NULL
14	NULL
]	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cytokines	NULL
such	NULL
as	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
have	NULL
little	NULL
capacity	NULL
to	NULL
elicit	NULL
these	NULL
responses	NULL
.	NULL

Rather	NULL
,	NULL
they	NULL
greatly	NULL
enhance	NULL
or	NULL
prime	NULL
the	NULL
response	NULL
of	NULL
neutrophils	NULL
to	NULL
other	NULL
agents	NULL
[	NULL
15	NULL
]	NULL
.	NULL

Receptors	NULL
for	NULL
the	NULL
two	NULL
classes	NULL
of	NULL
stimulus	NULL
similarly	NULL
have	NULL
contrasting	NULL
structures	NULL
and	NULL
signal	NULL
mechanisms	NULL
.	NULL

For	NULL
example	NULL
,	NULL
receptors	NULL
for	NULL
the	NULL
chemotactic	NULL
factors	NULL
,	NULL
but	NULL
not	NULL
those	NULL
for	NULL
the	NULL
cytokines	NULL
,	NULL
operate	NULL
through	NULL
G-proteins	NULL
[	NULL
14	NULL
]	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
these	NULL
differences	NULL
,	NULL
chemotactic	NULL
factors	NULL
and	NULL
cytokines	NULL
share	NULL
an	NULL
ability	NULL
to	NULL
activate	NULL
extracellular	NULL
signal-regulated	NULL
protein	NULL
kinases	NULL
(	NULL
ERKs	NULL
)	NULL
[	NULL
16-18	NULL
]	NULL
.	NULL

However	NULL
,	NULL
studies	NULL
have	NULL
yet	NULL
to	NULL
establish	NULL
a	NULL
direct	NULL
link	NULL
between	NULL
these	NULL
kinases	NULL
and	NULL
neutrophil	NULL
function	NULL
[	NULL
19-21	NULL
]	NULL
.	NULL

Whereas	NULL
ERKs	NULL
are	NULL
known	NULL
to	NULL
activate	NULL
transcription	NULL
factors	NULL
in	NULL
numerous	NULL
cell	NULL
types	NULL
[	NULL
22	NULL
]	NULL
,	NULL
neutrophils	NULL
are	NULL
terminally	NULL
differentiated	NULL
,	NULL
non-mitotic	NULL
,	NULL
short-lived	NULL
cells	NULL
whose	NULL
principal	NULL
responses	NULL
are	NULL
largely	NULL
independent	NULL
of	NULL
protein	NULL
synthesis	NULL
.	NULL

Regulation	NULL
of	NULL
gene	NULL
expression	NULL
would	NULL
not	NULL
be	NULL
crucial	NULL
to	NULL
the	NULL
functioning	NULL
of	NULL
ERK	NULL
in	NULL
cells	NULL
with	NULL
the	NULL
latter	NULL
characteristics	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
neutrophils	NULL
do	NULL
increase	NULL
the	NULL
transcription	NULL
of	NULL
chemokine	NULL
,	NULL
cytokine	NULL
,	NULL
and	NULL
immediate-early	NULL
genes	NULL
during	NULL
stimulation	NULL
[	NULL
23-25	NULL
]	NULL
.	NULL

Furthermore	NULL
,	NULL
recent	NULL
studies	NULL
find	NULL
that	NULL
neutrophils	NULL
contain	NULL
several	NULL
STAT	NULL
's	NULL
(	NULL
including	NULL
STAT3	NULL
)	NULL
that	NULL
are	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
during	NULL
challenge	NULL
with	NULL
GM-CSF	NULL
or	NULL
G-CSF	NULL
[	NULL
26-28	NULL
]	NULL
.	NULL

Here	NULL
we	NULL
test	NULL
the	NULL
notion	NULL
that	NULL
STAT3	NULL
is	NULL
a	NULL
physiological	NULL
target	NULL
for	NULL
ERKs	NULL
in	NULL
human	NULL
neutrophils	NULL
.	NULL

We	NULL
find	NULL
that	NULL
the	NULL
serine	NULL
phosphorylation	NULL
of	NULL
Abbreviations	NULL
used	NULL
:	NULL
ERK	NULL
,	NULL
extracellular	NULL
signal-regulated	NULL
protein	NULL
kinase	NULL
;	NULL
FMLP	NULL
,	NULL
N-formyl-methionyl-leucyl-phenylalanine	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte/	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
G-CSF	NULL
,	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
H7	NULL
,	NULL
1-	NULL
(	NULL
5-isoquinolinylsulphonyl	NULL
)	NULL
-2-methylpiperazine	NULL
dihydro-chloride	NULL
;	NULL
MAP	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
;	NULL
p90	NULL
``	NULL
,	NULL
90	NULL
kDa	NULL
ribosomal	NULL
S6	NULL
kinase	NULL
;	NULL
PD	NULL
98059	NULL
,	NULL
(	NULL
Z-amino-3'-methoxyphenyljoxanaphthalen-4-one	NULL
;	NULL
SB	NULL
203580	NULL
,	NULL
4-	NULL
(	NULL
4-fluorophenyl	NULL
)	NULL
-2-	NULL
(	NULL
4-methylsulphinylphenyl	NULL
)	NULL
-5-	NULL
(	NULL
4-pyridy1	NULL
)	NULL
1H-imidazole	NULL
;	NULL
STAT	NULL
,	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
.	NULL

!	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
(	NULL
e-mail	NULL
joflaher	NULL
@	NULL
wfubmc.edu	NULL
)	NULL
.	NULL

©	NULL
1999	NULL
Biochemical	NULL
Society	NULL
692	NULL
M.	NULL
Kuroki	NULL
and	NULL
J.	NULL
T.	NULL
O'Flaherty	NULL
STAT3	NULL
is	NULL
mediated	NULL
by	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
pathways	NULL
,	NULL
one	NULL
requiring	NULL
ERK	NULL
activation	NULL
and	NULL
the	NULL
other	NULL
independent	NULL
of	NULL
it	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Antibodies	NULL
and	NULL
reagents	NULL
Phospho-specific	NULL
antibodies	NULL
for	NULL
STAT3	NULL
and	NULL
ERK	NULL
were	NULL
obtained	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
(	NULL
Beverly	NULL
,	NULL
MA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
against	NULL
STAT3	NULL
and	NULL
90	NULL
kDa	NULL
ribosomal	NULL
S6	NULL
kinase	NULL
(	NULL
p90	NULL
``	NULL
**	NULL
)	NULL
,	NULL
and	NULL
secondary	NULL
antibodies	NULL
conjugated	NULL
with	NULL
horseradish	NULL
peroxidase	NULL
,	NULL
were	NULL
from	NULL
Transduction	NULL
Laboratories	NULL
(	NULL
Lexington	NULL
,	NULL
KY	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

(	NULL
2-Amino-3'-methoxyphenyl	NULL
)	NULL
oxanaphthalen-4-one	NULL
(	NULL
PD	NULL
98059	NULL
)	NULL
and	NULL
4-	NULL
(	NULL
4-fluorophenyl	NULL
)	NULL
-2-	NULL
(	NULL
4-methylsulphinylphenyl	NULL
)	NULL
-5-	NULL
(	NULL
4-pyridyl	NULL
)	NULL
1H-imidazole	NULL
(	NULL
SB	NULL
203580	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Calbiochem	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
and	NULL
dissolved	NULL
in	NULL
DMSO	NULL
.	NULL

1-	NULL
(	NULL
5-Isoquinolinylsulphonyl	NULL
)	NULL
-2-methylpiperazine	NULL
dihydrochloride	NULL
(	NULL
H7	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Alexis	NULL
Biochemicals	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
and	NULL
Research	NULL
Biochemicals	NULL
International	NULL
(	NULL
Natick	NULL
,	NULL
MA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Reagents	NULL
from	NULL
the	NULL
two	NULL
sources	NULL
gave	NULL
comparable	NULL
results	NULL
.	NULL

Recombinant	NULL
human	NULL
GM-CSF	NULL
and	NULL
G-CSF	NULL
were	NULL
from	NULL
Pepro	NULL
Tech	NULL
(	NULL
Rocky	NULL
Hill	NULL
,	NULL
NJ	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

CSa	NULL
and	NULL
PMA	NULL
were	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

FMLP	NULL
was	NULL
from	NULL
Peninsula	NULL
Laboratories	NULL
(	NULL
Belmont	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
cells	NULL
Human	NULL
neutrophils	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
fresh	NULL
venous	NULL
blood	NULL
of	NULL
healthy	NULL
volunteers	NULL
.	NULL

Cells	NULL
were	NULL
suspended	NULL
in	NULL
a	NULL
modified	NULL
Hanks	NULL
balanced	NULL
salt	NULL
solution	NULL
[	NULL
18	NULL
]	NULL
and	NULL
stored	NULL
on	NULL
ice	NULL
before	NULL
use	NULL
.	NULL

Immunoblotting	NULL
studies	NULL
Cells	NULL
[	NULL
(	NULL
2-4	NULL
)	NULL
x	NULL
105/mll	NULL
were	NULL
challenged	NULL
at	NULL
37°C	NULL
and	NULL
pelleted	NULL
by	NULL
rapid	NULL
centrifugation	NULL
.	NULL

Pellets	NULL
were	NULL
suspended	NULL
in	NULL
ice-cold	NULL
sample	NULL
buffer	NULL
[	NULL
20	NULL
mM	NULL
Tris/HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
/2	NULL
mM	NULL
EDTA/50	NULL
mM	NULL
2-mercaptocthanol/25	NULL
mM	NULL
NaF/0.2	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
/2	NULL
mM	NULL
di-isopropylfluorophosphate/1	NULL
mM	NULL
PMSF/25	NULL
ug/ml	NULL
pepstatin/	NULL
40	NULL
ug/ml	NULL
leupeptin/50	NULL
i.u./ml	NULL
aprotinin	NULL
]	NULL
and	NULL
placed	NULL
on	NULL
ice	NULL
for	NULL
15-30	NULL
min	NULL
.	NULL

The	NULL
suspensions	NULL
were	NULL
combined	NULL
with	NULL
equal	NULL
volumes	NULL
of	NULL
2x	NULL
SDS	NULL
sample	NULL
buffer	NULL
[	NULL
1	NULL
x	NULL
buffer	NULL
:	NULL
62.5	NULL
mM	NULL
Tris/HCl	NULL
(	NULL
pH	NULL
6.8	NULL
)	NULL
/2	NULL
%	NULL
SDS/50	NULL
mM	NULL
dithiothreitol	NULL
]	NULL
and	NULL
immediately	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
.	NULL

For	NULL
STATs	NULL
and	NULL
p90	NULL
``	NULL
**	NULL
,	NULL
samples	NULL
were	NULL
subjected	NULL
to	NULL
SDS/	NULL
PAGE	NULL
[	NULL
8	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
gell	NULL
and	NULL
electroblotted	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
.	NULL

For	NULL
ERKs	NULL
,	NULL
samples	NULL
were	NULL
subjected	NULL
to	NULL
SDS/PAGE	NULL
[	NULL
12	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
gel	NULL
]	NULL
and	NULL
electroblotted	NULL
to	NULL
PVDF	NULL
membranes	NULL
.	NULL

Membranes	NULL
were	NULL
blocked	NULL
with	NULL
3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
non-fat	NULL
milk	NULL
in	NULL
Tris-buffered	NULL
saline/Tween	NULL
20	NULL
(	NULL
TBS-T	NULL
)	NULL
[	NULL
10	NULL
mM	NULL
Tris/HCl	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
/154	NULL
mM	NULL
NaC1/0.1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Tween	NULL
20	NULL
]	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
1	NULL
h	NULL
,	NULL
washed	NULL
in	NULL
TBS-T	NULL
and	NULL
incubated	NULL
with	NULL
primary	NULL
antibody	NULL
(	NULL
1:2000	NULL
dilution	NULL
)	NULL
in	NULL
TBS-T	NULL
containing	NULL
1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
BSA	NULL
.	NULL

Blots	NULL
were	NULL
washed	NULL
in	NULL
TBS-T	NULL
before	NULL
incubation	NULL
for	NULL
1	NULL
h	NULL
with	NULL
a	NULL
secondary	NULL
antibody	NULL
(	NULL
1	NULL
:	NULL
5000	NULL
dilution	NULL
)	NULL
,	NULL
either	NULL
horseradish	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
or	NULL
horseradish	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-rabbit	NULL
IgG	NULL
,	NULL
in	NULL
TBS-T	NULL
containing	NULL
1.5	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
non-fat	NULL
milk	NULL
.	NULL

Blots	NULL
were	NULL
washed	NULL
extensively	NULL
with	NULL
TBS-T	NULL
and	NULL
proteins	NULL
were	NULL
detected	NULL
with	NULL
an	NULL
enhanced	NULL
chemiluminescence	NULL
detection	NULL
system	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
two	NULL
or	NULL
three	NULL
experiments	NULL
done	NULL
on	NULL
cells	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

RESULTS	NULL
To	NULL
determine	NULL
the	NULL
effect	NULL
of	NULL
FMLP	NULL
and	NULL
GM-CSF	NULL
on	NULL
ERKs	NULL
,	NULL
neutrophils	NULL
were	NULL
stimulated	NULL
with	NULL
FMLP	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
or	NULL
GM-CSF	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
for	NULL
1-60	NULL
min	NULL
.	NULL

After	NULL
stimulation	NULL
,	NULL
ERKs	NULL
were	NULL
©	NULL
1999	NULL
Biochemical	NULL
Society	NULL
``	NULL
C	NULL
FMLP	NULL
T	NULL
time	NULL
(	NULL
min	NULL
)	NULL
8	NULL
1	NULL
5	NULL
15	NULL
30	NULL
60	NULL
ERK1/2=-p*	NULL
ls	NULL
His	NULL
Ts	NULL
Ze	NULL
.	NULL

--	NULL
+	NULL
PD	NULL
98059	NULL
E	NULL
GM-CSF	NULL
i=	NULL
time	NULL
(	NULL
min	NULL
)	NULL
8	NULL
1	NULL
5	NULL
15	NULL
30	NULL
60	NULL
--	NULL
E	NULL
-i-ERK1/2-	NULL
»	NULL
>	NULL
``	NULL
+	NULL
PD	NULL
98059	NULL
Figure	NULL
1	NULL
Effect	NULL
of	NULL
PD	NULL
98059	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
ERKs	NULL
In	NULL
varlably	NULL
stimulated	NULL
neutrophils	NULL
Cells	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
or	NULL
PD	NULL
$	NULL
8059	NULL
(	NULL
50	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
before	NULL
stimulation	NULL
with	NULL
FMLP	NULL
(	NULL
1	NULL
M	NULL
)	NULL
or	NULL
GM-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
times	NULL
(	NULL
in	NULL
min	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
subjected	NULL
to	NULL
immunoblot	NULL
analysis	NULL
with	NULL
anti-phospho	NULL
(	NULL
Thr-202/Tyr-204	NULL
)	NULL
ERK	NULL
antibody	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
positions	NULL
of	NULL
phosphorylated	NULL
ERK1	NULL
(	NULL
upper	NULL
band	NULL
)	NULL
and	NULL
ERK2	NULL
(	NULL
lower	NULL
band	NULL
)	NULL
.	NULL

evaluated	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
the	NULL
activated	NULL
forms	NULL
of	NULL
ERK1	NULL
and	NULL
ERK2	NULL
.	NULL

The	NULL
antibody	NULL
recognizes	NULL
the	NULL
kinases	NULL
only	NULL
when	NULL
phosphorylated	NULL
on	NULL
Thr-202	NULL
and	NULL
Tyr-204	NULL
residues	NULL
in	NULL
their	NULL
regulatory	NULL
sequence	NULL
.	NULL

FMLP	NULL
and	NULL
GM-CSF	NULL
stimulated	NULL
the	NULL
dual	NULL
phosphorylation	NULL
of	NULL
both	NULL
ERK	NULL
s	NULL
but	NULL
operated	NULL
with	NULL
different	NULL
kinetics	NULL
.	NULL

Responses	NULL
to	NULL
FMLP	NULL
were	NULL
rapid	NULL
and	NULL
transient	NULL
,	NULL
maximizing	NULL
within	NULL
1	NULL
min	NULL
and	NULL
decreasing	NULL
thereafter	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

Responses	NULL
to	NULL
GM-CSF	NULL
developed	NULL
only	NULL
after	NULL
1	NULL
min	NULL
,	NULL
reached	NULL
a	NULL
maximum	NULL
by	NULL
5-15	NULL
min	NULL
and	NULL
declined	NULL
slowly	NULL
over	NULL
60	NULL
min	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

PD	NULL
98059	NULL
inhibits	NULL
ERK	NULL
activation	NULL
by	NULL
preventing	NULL
the	NULL
activation	NULL
of	NULL
MAP	NULL
kinase	NULL
kinase	NULL
1	NULL
[	NULL
29	NULL
]	NULL
.	NULL

As	NULL
reported	NULL
previously	NULL
[	NULL
19-21	NULL
]	NULL
,	NULL
the	NULL
drug	NULL
(	NULL
50	NULL
zM	NULL
)	NULL
almost	NULL
completely	NULL
blocked	NULL
FMLP-	NULL
and	NULL
GM-CSF	NULL
-induced	NULL
ERK	NULL
phosphorylation	NULL
regardless	NULL
of	NULL
duration	NULL
of	NULL
stimulation	NULL
(	NULL
160	NULL
min	NULL
)	NULL
.	NULL

PD	NULL
98059	NULL
similarly	NULL
blocked	NULL
the	NULL
activation	NULL
of	NULL
ERKs	NULL
stimulated	NULL
by	NULL
CSa	NULL
or	NULL
PMA	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
however	NULL
,	NULL
G-CSF	NULL
had	NULL
relatively	NULL
little	NULL
ability	NULL
to	NULL
stimulate	NULL
ERK	NULL
activation	NULL
(	NULL
see	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

The	NULL
ribosomal	NULL
protein	NULL
kinase	NULL
p90	NULL
``	NULL
®	NULL
``	NULL
is	NULL
a	NULL
downstream	NULL
target	NULL
for	NULL
the	NULL
ERKs	NULL
that	NULL
,	NULL
on	NULL
phosphorylation	NULL
at	NULL
multiple	NULL
sites	NULL
,	NULL
exhibits	NULL
a	NULL
characteristic	NULL
decrease	NULL
in	NULL
its	NULL
electrophoretic	NULL
mobility	NULL
on	NULL
SDS/	NULL
PAGE	NULL
[	NULL
30	NULL
]	NULL
.	NULL

We	NULL
used	NULL
this	NULL
mobility	NULL
change	NULL
to	NULL
monitor	NULL
ERK	NULL
activation	NULL
in	NULL
vivo	NULL
.	NULL

Figure	NULL
2	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
indicates	NULL
that	NULL
p90	NULL
``	NULL
appeared	NULL
as	NULL
a	NULL
doublet	NULL
in	NULL
the	NULL
lysates	NULL
of	NULL
resting	NULL
neutrophils	NULL
.	NULL

Challenging	NULL
the	NULL
cells	NULL
with	NULL
FMLP	NULL
or	NULL
CSa	NULL
caused	NULL
the	NULL
appearance	NULL
of	NULL
multiple	NULL
slower-moving	NULL
p90	NULL
``	NULL
*	NULL
``	NULL
*	NULL
species	NULL
.	NULL

PD	NULL
98059	NULL
blocked	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
latter	NULL
species	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

These	NULL
results	NULL
,	NULL
when	NULL
taken	NULL
with	NULL
those	NULL
on	NULL
ERK	NULL
phosphorylation	NULL
,	NULL
establish	NULL
that	NULL
PD	NULL
98059	NULL
efficiently	NULL
blocks	NULL
the	NULL
activation	NULL
of	NULL
ERKs	NULL
in	NULL
stimulated	NULL
neutrophils	NULL
.	NULL

We	NULL
next	NULL
probed	NULL
for	NULL
stimulus-induced	NULL
changes	NULL
in	NULL
the	NULL
disposition	NULL
of	NULL
STAT3	NULL
by	NULL
immunoblotting	NULL
cell	NULL
lysates	NULL
with	NULL
anti-STAT3	NULL
antibody	NULL
.	NULL

Figure	NULL
2	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
shows	NULL
that	NULL
the	NULL
STAT3	NULL
in	NULL
resting	NULL
neutrophils	NULL
seemed	NULL
to	NULL
be	NULL
a	NULL
doublet	NULL
,	NULL
with	NULL
most	NULL
material	NULL
migrating	NULL
as	NULL
the	NULL
faster	NULL
species	NULL
.	NULL

However	NULL
,	NULL
after	NULL
a	NULL
1	NULL
min	NULL
challenge	NULL
of	NULL
cells	NULL
with	NULL
FMLP	NULL
(	NULL
1	NULL
nM	NULL
or	NULL
1	NULL
wM	NULL
)	NULL
or	NULL
CSa	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
,	NULL
the	NULL
protein	NULL
displayed	NULL
an	NULL
up-shift	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
Regulation	NULL
of	NULL
STAT3	NULL
by	NULL
extracellular	NULL
signal-regulated	NULL
protein	NULL
kinases	NULL
693	NULL
PD	NULL
98059	NULL
(	NULL
M	NULL
)	NULL
-	NULL
0.5	NULL
5	NULL
50	NULL
-	NULL
§	NULL
50	NULL
-	NULL
0.5	NULL
5	NULL
50	NULL
pQUFEkE	NULL
--	NULL
!	NULL

-i-	NULL
_____=i-—_r.—	NULL
FMLP	NULL
(	NULL
1	NULL
pM	NULL
)	NULL
-	NULL
FMLP	NULL
(	NULL
1	NULL
nM	NULL
)	NULL
C_	NULL
CSa	NULL
(	NULL
0.1	NULL
pM	NULL
)	NULL
PD	NULL
98059	NULL
(	NULL
uM	NULL
)	NULL
--	NULL
5	NULL
50	NULL
-	NULL
5	NULL
50	NULL
-	NULL
_-	NULL
50	NULL
STAT3	NULL
4	NULL
®	NULL
»	NULL
~-	NULL
»	NULL
Ws	NULL
|	NULL
Us	NULL
%	NULL
oan	NULL
FMLP	NULL
FMLP	NULL
C	NULL
-	NULL
CSa	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
(	NULL
1	NULL
nM	NULL
)	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
Figure	NULL
2	NULL
-	NULL
Effects	NULL
of	NULL
PD	NULL
98059	NULL
on	NULL
the	NULL
change	NULL
In	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
p90**	NULL
and	NULL
STAT3	NULL
In	NULL
neutrophils	NULL
stimulated	NULL
by	NULL
chemotactic	NULL
factors	NULL
Cells	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
or	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
PD	NULL
$	NULL
8059	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
FMLP	NULL
or	NULL
CSa	NULL
for	NULL
1	NULL
min	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
immunoblotted	NULL
with	NULL
antibody	NULL
against	NULL
p90	NULL
``	NULL
*	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
STAT3	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

5	NULL
3	NULL
i	NULL
§	NULL
$	NULL
$	NULL
&	NULL
&	NULL
€	NULL
-	NULL
£	NULL
&	NULL
so	NULL
9	NULL
$	NULL
&	NULL
%	NULL
o	NULL
&	NULL
5	NULL
&	NULL
a	NULL
STAT3	NULL
-	NULL
»	NULL
cmm	NULL
-	NULL
emma	NULL
>	NULL
>	NULL
ene	NULL
ERK1	NULL
ERK2-	NULL
»	NULL
Grass	NULL
Figure	NULL
3	NULL
-	NULL
Phosphorylation	NULL
of	NULL
STAT3	NULL
and	NULL
ERKs	NULL
In	NULL
stimulated	NULL
neutrophils	NULL
Cells	NULL
were	NULL
left	NULL
unstimulated	NULL
or	NULL
were	NULL
stimulated	NULL
with	NULL
FMLP	NULL
(	NULL
1	NULL
&	NULL
M	NULL
)	NULL
or	NULL
CSa	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
for	NULL
1	NULL
min	NULL
or	NULL
with	NULL
GM-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

,	NULL
G-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
PMA	NULL
(	NULL
160	NULL
nM	NULL
)	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-phospho	NULL
(	NULL
Ser-727	NULL
)	NULL
STAT3	NULL
antibody	NULL
or	NULL
anti-phospho	NULL
(	NULL
Thr-202/Tyr-204	NULL
)	NULL
ERK	NULL
antibody	NULL
.	NULL

earlier	NULL
work	NULL
[	NULL
4-11	NULL
]	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
STAT3	NULL
becomes	NULL
phosphorylated	NULL
on	NULL
serine	NULL
or	NULL
threonine	NULL
during	NULL
neutrophil	NULL
stimulation	NULL
.	NULL

To	NULL
confirm	NULL
this	NULL
and	NULL
to	NULL
define	NULL
the	NULL
site	NULL
of	NULL
phosphorylation	NULL
,	NULL
we	NULL
probed	NULL
blots	NULL
with	NULL
an	NULL
antibody	NULL
specifically	NULL
recognizing	NULL
STAT3	NULL
phosphorylated	NULL
on	NULL
Ser-727	NULL
.	NULL

Resting	NULL
neutrophils	NULL
contained	NULL
a	NULL
band	NULL
faintly	NULL
reactive	NULL
with	NULL
the	NULL
antibody	NULL
.	NULL

The	NULL
intensity	NULL
of	NULL
this	NULL
band	NULL
increased	NULL
in	NULL
cells	NULL
challenged	NULL
with	NULL
CSa	NULL
,	NULL
FMLP	NULL
,	NULL
GM-CSF	NULL
,	NULL
G-CSF	NULL
or	NULL
PMA	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

Thus	NULL
stimuli	NULL
that	NULL
activate	NULL
ERKs	NULL
generally	NULL
induced	NULL
neutrophils	NULL
to	NULL
phosphorylate	NULL
STAT3	NULL
on	NULL
Ser-727	NULL
;	NULL
however	NULL
,	NULL
the	NULL
two	NULL
responses	NULL
do	NULL
show	NULL
some	NULL
divergence	NULL
.	NULL

FMLP	NULL
,	NULL
CS5a	NULL
,	NULL
and	NULL
PMA	NULL
strongly	NULL
stimulated	NULL
ERK	NULL
activation	NULL
and	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
,	NULL
whereas	NULL
GM-CSF	NULL
and	NULL
G-CSF	NULL
,	NULL
although	NULL
eliciting	NULL
appreciable	NULL
serine	NULL
phosphorylation	NULL
responses	NULL
,	NULL
had	NULL
respectively	NULL
less	NULL
or	NULL
almost	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
ERKs	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

This	NULL
result	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
some	NULL
kinase	NULL
besides	NULL
the	NULL
ERK	NULL
s	NULL
is	NULL
at	NULL
least	NULL
partly	NULL
responsible	NULL
for	NULL
phosphorylating	NULL
STAT3	NULL
on	NULL
Ser-727	NULL
in	NULL
cytokine-stimulated	NULL
neutrophils	NULL
.	NULL

PD	NULL
98059	NULL
almost	NULL
totally	NULL
blocked	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
responses	NULL
to	NULL
FMLP	NULL
and	NULL
CSa	NULL
when	NULL
judged	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
changes	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
or	NULL
immuno-	NULL
FMLP	NULL
ease	NULL
am	NULL
ant	NULL
«	NULL
hus	NULL
+	NULL
PD	NULL
98059	NULL
«	NULL
ame	NULL
:	NULL
aime	NULL
ants	NULL
GM-CSF	NULL
+	NULL
PD	NULL
98059	NULL
causes	NULL
.	NULL

commie	NULL
C	NULL
1	NULL
5	NULL
15	NULL
30	NULL
60	NULL
time	NULL
(	NULL
min	NULL
)	NULL
Figure	NULL
4	NULL
-	NULL
Kinetics	NULL
of	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
on	NULL
Ser-727	NULL
In	NULL
stimulated	NULL
neutrophils	NULL
Cells	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
or	NULL
PD	NULL
98059	NULL
(	NULL
50	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
FMLP	NULL
(	NULL
1	NULL
M	NULL
)	NULL
or	NULL
GM-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
durations	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-phospho	NULL
(	NULL
Ser-727	NULL
)	NULL
STAT3	NULL
antibody	NULL
.	NULL

Control	NULL
GM-CSF	NULL
FMLP	NULL
G-CSF	NULL
®	NULL
+	NULL
=	NULL
+	NULL
B	NULL
+	NULL
-	NULL
+	NULL
PD	NULL
98059	NULL
comms	NULL
i	NULL
%	NULL
isis	NULL
H7	NULL
.	NULL

Amis	NULL
.	NULL

P	NULL
Figure	NULL
5	NULL
-	NULL
Effects	NULL
of	NULL
PD	NULL
98059	NULL
and	NULL
H7	NULL
on	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
In	NULL
varlably	NULL
stimulated	NULL
neutrophils	NULL
Cells	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
,	NULL
PD	NULL
98059	NULL
(	NULL
50	NULL
M	NULL
)	NULL
or	NULL
H7	NULL
(	NULL
50	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
FMLP	NULL
(	NULL
1	NULL
M	NULL
)	NULL
,	NULL
GM-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
G-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
15	NULL
min	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-phospho	NULL
(	NULL
Ser-727	NULL
)	NULL
STAT3	NULL
antibody	NULL
.	NULL

In	NULL
studies	NULL
not	NULL
shown	NULL
,	NULL
PD	NULL
98059	NULL
(	NULL
50	NULL
M	NULL
)	NULL
failed	NULL
to	NULL
inhibit	NULL
the	NULL
sering	NULL
phosphorylation	NULL
response	NULL
to	NULL
a	NULL
5	NULL
,	NULL
30	NULL
or	NULL
60	NULL
min	NULL
challenge	NULL
with	NULL
G-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

reactivity	NULL
with	NULL
phospho	NULL
(	NULL
Ser-727	NULL
)	NULL
STAT3	NULL
antibody	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
PD	NULL
98059	NULL
profoundly	NULL
inhibited	NULL
responses	NULL
to	NULL
PMA	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
drug	NULL
proved	NULL
far	NULL
less	NULL
effective	NULL
on	NULL
cytokines	NULL
.	NULL

This	NULL
is	NULL
best	NULL
seen	NULL
in	NULL
analyses	NULL
of	NULL
the	NULL
stimuli	NULL
's	NULL
actions	NULL
over	NULL
time	NULL
.	NULL

The	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
response	NULL
to	NULL
FMLP	NULL
was	NULL
evident	NULL
at	NULL
1	NULL
min	NULL
,	NULL
reached	NULL
a	NULL
maximum	NULL
by	NULL
15	NULL
min	NULL
and	NULL
remained	NULL
elevated	NULL
for	NULL
60	NULL
min	NULL
.	NULL

PD	NULL
98059	NULL
almost	NULL
totally	NULL
abrogated	NULL
this	NULL
response	NULL
at	NULL
all	NULL
durations	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

The	NULL
GM-CSF-induced	NULL
response	NULL
was	NULL
detectable	NULL
within	NULL
5	NULL
min	NULL
,	NULL
was	NULL
maximized	NULL
at	NULL
15	NULL
min	NULL
and	NULL
lasted	NULL
for	NULL
60	NULL
min	NULL
.	NULL

PD	NULL
98059	NULL
strongly	NULL
blocked	NULL
the	NULL
response	NULL
developing	NULL
at	NULL
5	NULL
or	NULL
60	NULL
min	NULL
but	NULL
not	NULL
15	NULL
or	NULL
30	NULL
min	NULL
after	NULL
cytokine	NULL
challenge	NULL
.	NULL

The	NULL
response	NULL
at	NULL
30	NULL
min	NULL
,	NULL
in	NULL
particular	NULL
,	NULL
was	NULL
decreased	NULL
only	NULL
marginally	NULL
by	NULL
the	NULL
drug	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
PD	NULL
98059	NULL
failed	NULL
to	NULL
decrease	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
responses	NULL
to	NULL
G-CSF	NULL
after	NULL
15	NULL
min	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
as	NULL
well	NULL
as	NULL
after	NULL
5	NULL
,	NULL
30	NULL
and	NULL
60	NULL
min	NULL
of	NULL
stimulation	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Evidently	NULL
,	NULL
therefore	NULL
,	NULL
stimulated	NULL
neutrophils	NULL
can	NULL
phosphorylate	NULL
STAT3	NULL
Ser-727	NULL
through	NULL
ERK	NULL
-independent	NULL
and	NULL
ERK	NULL
-dependent	NULL
pathways	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
implicated	NULL
one	NULL
or	NULL
more	NULL
H7-sensitive	NULL
serine	NULL
kinases	NULL
in	NULL
the	NULL
STAT3	NULL
serine-phosphorylation	NULL
responses	NULL
of	NULL
some	NULL
cells	NULL
[	NULL
6,7,11,12	NULL
]	NULL
.	NULL

As	NULL
illustrated	NULL
in	NULL
the	NULL
lower	NULL
part	NULL
of	NULL
Figure	NULL
5	NULL
,	NULL
however	NULL
,	NULL
stimulus-induced	NULL
serine	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
was	NULL
not	NULL
significantly	NULL
changed	NULL
by	NULL
H7	NULL
in	NULL
neutrophils	NULL
.	NULL

The	NULL
drug	NULL
did	NULL
block	NULL
baseline	NULL
up-shifts	NULL
in	NULL
the	NULL
electro-	NULL
©	NULL
1999	NULL
Biochemical	NULL
Society	NULL
694	NULL
M.	NULL
Kuroki	NULL
and	NULL
J.	NULL
T.	NULL
O'Flaherty	NULL
ed	NULL
“	NULL
IQ	NULL
6	NULL
-	NULL
a	NULL
$	NULL
-	NULL
$	NULL
0	NULL
a	NULL
&	NULL
&	NULL
£	NULL
§	NULL
s	NULL
If	NULL
#	NULL
$	NULL
S	NULL
g	NULL
go	NULL
4	NULL
o	NULL
r	NULL
ae	NULL
-~	NULL
Uh	NULL
Figure	NULL
6	NULL
Effects	NULL
of	NULL
various	NULL
stimull	NULL
on	NULL
the	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
at	NULL
Tyr-705	NULL
In	NULL
neutrophils	NULL
Cells	NULL
were	NULL
left	NULL
unstimulated	NULL
or	NULL
were	NULL
stimulated	NULL
with	NULL
FMLP	NULL
(	NULL
1	NULL
&	NULL
M	NULL
)	NULL
or	NULL
CSa	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
for	NULL
1	NULL
min	NULL
or	NULL
with	NULL
GM-CSF	NULL
(	NULL
500	NULL
ng/m1	NULL
)	NULL
,	NULL
G-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
PMA	NULL
(	NULL
160	NULL
nM	NULL
)	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Lysates	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-phospho	NULL
(	NULL
Tyr-705	NULL
)	NULL
STAT3	NULL
antibody	NULL
.	NULL

GM-CSF	NULL
Control	NULL
naaa	NULL
ua	NULL
+	NULL
PD	NULL
98059	NULL
aan	NULL
p	NULL
<	NULL
n	NULL
ei	NULL
<	NULL
»	NULL
C	NULL
5	NULL
15	NULL
30	NULL
45	NULL
_	NULL
60	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
G-CSF	NULL
Control	NULL
ow	NULL
:	NULL
inp	NULL
me	NULL
os	NULL
+	NULL
PD	NULL
98059	NULL
L	NULL
»	NULL
@	NULL
»	NULL
«	NULL
»	NULL
C	NULL
1	NULL
5	NULL
__	NULL
15	NULL
__30	NULL
60	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
Figure	NULL
7	NULL
-	NULL
Effect	NULL
of	NULL
PD	NULL
98059	NULL
on	NULL
the	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
(	NULL
Tyr-705	NULL
)	NULL
In	NULL
varlably	NULL
stimulated	NULL
neutrophils	NULL
Cells	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
or	NULL
PD	NULL
98059	NULL
(	NULL
50	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
left	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
GM-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
G-CSF	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
durations	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
immunoblotted	NULL
with	NULL
anti-phospho	NULL
(	NULL
Tyr-705	NULL
)	NULL
STAT3	NULL
antibody	NULL
.	NULL

phoretic	NULL
mobility	NULL
of	NULL
STAT1	NULL
on	NULL
SDS/PAGE	NULL
in	NULL
resting	NULL
cells	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
H7	NULL
seemed	NULL
active	NULL
in	NULL
neutrophils	NULL
.	NULL

SB	NULL
203580	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
p38	NULL
MAP	NULL
kinase	NULL
,	NULL
also	NULL
failed	NULL
to	NULL
block	NULL
STAT3	NULL
serine-phosphorylation	NULL
responses	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Because	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT	NULL
's	NULL
is	NULL
essential	NULL
for	NULL
activating	NULL
transcription	NULL
[	NULL
1-3	NULL
]	NULL
,	NULL
we	NULL
probed	NULL
neutrophil	NULL
lysates	NULL
with	NULL
an	NULL
antibody	NULL
specifically	NULL
recognizing	NULL
STAT3	NULL
phosphorylated	NULL
on	NULL
Tyr-705	NULL
.	NULL

The	NULL
results	NULL
confirmed	NULL
studies	NULL
[	NULL
26-28	NULL
]	NULL
showing	NULL
that	NULL
STAT3	NULL
is	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
in	NULL
cells	NULL
stimulated	NULL
by	NULL
GM-CSF	NULL
or	NULL
G-CSF	NULL
.	NULL

Neutrophil	NULL
STAT3	NULL
tyrosine	NULL
phosphorylation	NULL
responses	NULL
rose	NULL
to	NULL
maximal	NULL
levels	NULL
within	NULL
5-15	NULL
min	NULL
and	NULL
declined	NULL
thereafter	NULL
,	NULL
returning	NULL
to	NULL
near	NULL
baseline	NULL
levels	NULL
within	NULL
60	NULL
min	NULL
(	NULL
Figures	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
with	NULL
these	NULL
findings	NULL
,	NULL
there	NULL
was	NULL
no	NULL
detectable	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
at	NULL
any	NULL
time	NULL
(	NULL
1-60	NULL
min	NULL
)	NULL
in	NULL
cells	NULL
challenged	NULL
with	NULL
FMLP	NULL
,	NULL
CSa	NULL
or	NULL
PMA	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

Cytokines	NULL
thus	NULL
exhibit	NULL
a	NULL
basic	NULL
difference	NULL
from	NULL
chemotactic	NULL
factors	NULL
and	NULL
a	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
in	NULL
that	NULL
the	NULL
latter	NULL
stimuli	NULL
induce	NULL
the	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
on	NULL
serine	NULL
but	NULL
not	NULL
tyrosine	NULL
.	NULL

In	NULL
a	NULL
final	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
PD	NULL
98059	NULL
increased	NULL
the	NULL
extent	NULL
of	NULL
STAT3	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
cells	NULL
challenged	NULL
with	NULL
GM-CSF	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
was	NULL
most	NULL
prominent	NULL
at	NULL
and	NULL
after	NULL
30	NULL
min	NULL
of	NULL
stimulation	NULL
.	NULL

The	NULL
drug	NULL
also	NULL
enhanced	NULL
STAT3	NULL
tyrosine	NULL
phosphorylation	NULL
responses	NULL
to	NULL
G-CSF	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
although	NULL
this	NULL
was	NULL
less	NULL
evident	NULL
than	NULL
that	NULL
observed	NULL
for	NULL
GM-CSF	NULL
.	NULL

We	NULL
note	NULL
that	NULL
G-CSF	NULL
was	NULL
similarly	NULL
less	NULL
©	NULL
1999	NULL
Biochemical	NULL
Society	NULL
effective	NULL
than	NULL
GM-CSF	NULL
in	NULL
stimulating	NULL
the	NULL
activation	NULL
of	NULL
ERKs	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
ERK	NULL
signalling	NULL
pathway	NULL
,	NULL
although	NULL
mediating	NULL
the	NULL
serine	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
,	NULL
negatively	NULL
influences	NULL
its	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
demonstrated	NULL
that	NULL
chemotactic	NULL
factors	NULL
,	NULL
cytokines	NULL
and	NULL
a	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
stimulate	NULL
neutrophils	NULL
to	NULL
phosphorylate	NULL
STAT3	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
site	NULL
of	NULL
phosphorylation	NULL
,	NULL
we	NULL
took	NULL
advantage	NULL
of	NULL
an	NULL
antibody	NULL
that	NULL
specifically	NULL
recognizes	NULL
the	NULL
form	NULL
of	NULL
STAT3	NULL
phosphorylated	NULL
on	NULL
Ser-727	NULL
.	NULL

Ser-727	NULL
is	NULL
located	NULL
in	NULL
a	NULL
consensus	NULL
site	NULL
for	NULL
the	NULL
MAP	NULL
kinase	NULL
family	NULL
of	NULL
proline-directed	NULL
kinases	NULL
.	NULL

This	NULL
site	NULL
was	NULL
in	NULL
fact	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
all	NULL
test	NULL
stimuli	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
PD	NULL
98059	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
ERK	NULL
activation	NULL
,	NULL
blocked	NULL
responses	NULL
to	NULL
FMLP	NULL
,	NULL
CSa	NULL
and	NULL
PMA	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
correlated	NULL
with	NULL
the	NULL
drug	NULL
's	NULL
ability	NULL
to	NULL
inhibit	NULL
the	NULL
activation	NULL
of	NULL
ERKs	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
and	NULL
the	NULL
phosphorylation	NULL
of	NULL
p90	NULL
``	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
,	NULL
a	NULL
downstream	NULL
target	NULL
for	NULL
ERKs	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
ERKs	NULL
are	NULL
the	NULL
prevailing	NULL
upstream	NULL
kinases	NULL
for	NULL
phosphorylating	NULL
STAT3	NULL
on	NULL
Ser-727	NULL
in	NULL
human	NULL
neutrophils	NULL
challenged	NULL
with	NULL
chemotactic	NULL
factors	NULL
or	NULL
a	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PD	NULL
98059	NULL
proved	NULL
less	NULL
effective	NULL
in	NULL
decreasing	NULL
the	NULL
Ser-727	NULL
phosphorylation	NULL
caused	NULL
by	NULL
cytokines	NULL
.	NULL

It	NULL
only	NULL
partly	NULL
blocked	NULL
GM-CSF	NULL
in	NULL
cells	NULL
challenged	NULL
for	NULL
15-30	NULL
min	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
5	NULL
or	NULL
60	NULL
min	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
,	NULL
and	NULL
had	NULL
virtually	NULL
no	NULL
effect	NULL
on	NULL
responses	NULL
to	NULL
G-CSF	NULL
regardless	NULL
of	NULL
stimulating	NULL
time	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

The	NULL
insensitivity	NULL
of	NULL
G-CSF	NULL
to	NULL
PD	NULL
98059	NULL
,	NULL
along	NULL
with	NULL
its	NULL
minimal	NULL
effect	NULL
on	NULL
ERK	NULL
s	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
,	NULL
implies	NULL
that	NULL
an	NULL
ERK	NULL
-independent	NULL
pathway	NULL
bears	NULL
the	NULL
major	NULL
responsibility	NULL
for	NULL
mediating	NULL
the	NULL
serine	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
induced	NULL
by	NULL
this	NULL
cytokine	NULL
.	NULL

GM-CSF	NULL
caused	NULL
appreciable	NULL
ERK	NULL
activation	NULL
responses	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
and	NULL
,	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
PD	NULL
98059-sensitivity	NULL
studies	NULL
,	NULL
this	NULL
action	NULL
apparently	NULL
led	NULL
to	NULL
the	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
on	NULL
Ser-727	NULL
at	NULL
early	NULL
(	NULL
5	NULL
min	NULL
)	NULL
and	NULL
late	NULL
(	NULL
60	NULL
min	NULL
)	NULL
but	NULL
not	NULL
intermediate	NULL
(	NULL
15-30	NULL
min	NULL
)	NULL
times	NULL
of	NULL
stimulation	NULL
.	NULL

Because	NULL
tyrosine	NULL
phosphorylation	NULL
signals	NULL
for	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
STAT3	NULL
,	NULL
the	NULL
two	NULL
cytokines	NULL
,	NULL
but	NULL
not	NULL
chemotactic	NULL
factors	NULL
or	NULL
PMA	NULL
,	NULL
probably	NULL
caused	NULL
STAT3	NULL
to	NULL
enter	NULL
the	NULL
nucleus	NULL
.	NULL

The	NULL
nuclear	NULL
STAT3	NULL
might	NULL
then	NULL
be	NULL
dephosphorylated	NULL
and	NULL
exported	NULL
back	NULL
to	NULL
the	NULL
cytosol	NULL
.	NULL

These	NULL
events	NULL
could	NULL
explain	NULL
the	NULL
peculiar	NULL
time-dependence	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
PD	NULL
98059	NULL
on	NULL
GM-CSF	NULL
,	NULL
ie	NULL
.	NULL

ERKs	NULL
phosphorylate	NULL
cytosolic	NULL
STAT3	NULL
,	NULL
having	NULL
dominant	NULL
effects	NULL
at	NULL
early	NULL
and	NULL
late	NULL
times	NULL
,	NULL
whereas	NULL
a	NULL
PD	NULL
98059-insensitive	NULL
kinase	NULL
undertakes	NULL
this	NULL
phosphorylation	NULL
during	NULL
the	NULL
protein	NULL
's	NULL
residence	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
15-30	NULL
min	NULL
)	NULL
.	NULL

Figure	NULL
4	NULL
shows	NULL
that	NULL
STAT3	NULL
is	NULL
sub-optimally	NULL
tyrosine-phosphorylated	NULL
during	NULL
these	NULL
early	NULL
and	NULL
late	NULL
times	NULL
.	NULL

Recent	NULL
evidence	NULL
indicates	NULL
that	NULL
two	NULL
pathways	NULL
,	NULL
one	NULL
growth-factor-activated	NULL
and	NULL
ERK-dependent	NULL
,	NULL
the	NULL
other	NULL
interleukin-6-activated	NULL
and	NULL
ERK-independent	NULL
,	NULL
lead	NULL
to	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
[	NULL
11	NULL
]	NULL
.	NULL

The	NULL
latter	NULL
pathway	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
highly	NULL
sensitive	NULL
to	NULL
H7	NULL
[	NULL
6,7,11	NULL
]	NULL
.	NULL

Because	NULL
H7	NULL
had	NULL
no	NULL
such	NULL
effect	NULL
in	NULL
our	NULL
studies	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
,	NULL
the	NULL
H7-sensitive	NULL
kinase	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
serine-phosphorylating	NULL
STAT3	NULL
in	NULL
neutrophils	NULL
.	NULL

This	NULL
does	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
an	NULL
H7-sensitive	NULL
pathway	NULL
regulates	NULL
STAT3	NULL
binding	NULL
to	NULL
DNA	NULL
independently	NULL
of	NULL
Ser-727	NULL
phosphorylation	NULL
[	NULL
10	NULL
]	NULL
.	NULL

We	NULL
observed	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
that	NULL
SB	NULL
203580	NULL
,	NULL
a	NULL
p38	NULL
MAP	NULL
kinase	NULL
inhibitor	NULL
,	NULL
failed	NULL
to	NULL
decrease	NULL
serine	NULL
phosphorylation	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
recent	NULL
report	NULL
that	NULL
STAT3	NULL
is	NULL
a	NULL
poor	NULL
substrate	NULL
for	NULL
p38	NULL
MAP	NULL
kinase	NULL
in	NULL
vitro	NULL
[	NULL
11	NULL
]	NULL
.	NULL

We	NULL
note	NULL
that	NULL
neutrophils	NULL
,	NULL
like	NULL
other	NULL
cells	NULL
[	NULL
11	NULL
]	NULL
,	NULL
exhibited	NULL
an	NULL
enhanced	NULL
STAT3	NULL
tyrosine-phosphorylation	NULL
response	NULL
to	NULL
GM-CSF	NULL
and	NULL
,	NULL
to	NULL
a	NULL
smaller	NULL
extent	NULL
,	NULL
G-CSF	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PD	NULL
98059	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
ERK	NULL
pathway	NULL
Regulation	NULL
of	NULL
STAT3	NULL
by	NULL
extracellular	NULL
signal-regulated	NULL
protein	NULL
kinases	NULL
695	NULL
is	NULL
in	NULL
some	NULL
way	NULL
antagonistic	NULL
to	NULL
the	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
on	NULL
tyrosine	NULL
.	NULL

It	NULL
will	NULL
be	NULL
important	NULL
to	NULL
determine	NULL
whether	NULL
Ser-727	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
itself	NULL
or	NULL
,	NULL
alternatively	NULL
,	NULL
some	NULL
other	NULL
effect	NULL
of	NULL
the	NULL
ERK	NULL
signalling	NULL
pathway	NULL
is	NULL
responsible	NULL
for	NULL
this	NULL
negative	NULL
interaction	NULL
.	NULL

ERKs	NULL
have	NULL
numerous	NULL
targets	NULL
,	NULL
some	NULL
of	NULL
which	NULL
,	NULL
for	NULL
example	NULL
protein	NULL
tyrosine	NULL
phosphatase	NULL
,	NULL
might	NULL
limit	NULL
the	NULL
accumulation	NULL
of	NULL
tyrosine-phosphorylated	NULL
STAT3	NULL
.	NULL

Activation	NULL
of	NULL
STATs	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
occur	NULL
via	NULL
G-protein-coupled	NULL
receptors	NULL
such	NULL
as	NULL
the	NULL
AT	NULL
1	NULL
angiotensin	NULL
II	NULL
receptor	NULL
[	NULL
31-34	NULL
]	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
STAT3	NULL
is	NULL
not	NULL
tyrosine-phosphorylated	NULL
in	NULL
neutrophils	NULL
stimulated	NULL
with	NULL
FMLP	NULL
or	NULL
CSa	NULL
indicates	NULL
that	NULL
G-protein-coupled	NULL
receptors	NULL
are	NULL
not	NULL
universally	NULL
coupled	NULL
to	NULL
STAT	NULL
activation	NULL
responses	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

These	NULL
results	NULL
also	NULL
question	NULL
the	NULL
role	NULL
of	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
because	NULL
it	NULL
occurs	NULL
in	NULL
neutrophils	NULL
stimulated	NULL
with	NULL
chemotactic	NULL
factors	NULL
.	NULL

STAT	NULL
transcriptional	NULL
activity	NULL
is	NULL
absolutely	NULL
dependent	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
whereas	NULL
serine	NULL
phosphorylation	NULL
is	NULL
supplementary	NULL
:	NULL
the	NULL
latter	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
of	NULL
consequence	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
former	NULL
.	NULL

STAT3	NULL
serine	NULL
phosphorylation	NULL
might	NULL
be	NULL
a	NULL
byproduct	NULL
of	NULL
ERK	NULL
activation	NULL
,	NULL
making	NULL
no	NULL
contribution	NULL
to	NULL
the	NULL
action	NULL
of	NULL
chemotactic	NULL
factors	NULL
on	NULL
neutrophils	NULL
.	NULL

Alternatively	NULL
,	NULL
however	NULL
,	NULL
STAT3	NULL
serine	NULL
phosphorylation	NULL
might	NULL
participate	NULL
in	NULL
non-nuclear	NULL
signalling	NULL
,	NULL
a	NULL
notion	NULL
consistent	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
several	NULL
STAT	NULL
's	NULL
in	NULL
platelets	NULL
,	NULL
which	NULL
lack	NULL
nuclei	NULL
[	NULL
35	NULL
]	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
STAT3	NULL
can	NULL
operate	NULL
as	NULL
an	NULL
adaptor	NULL
protein	NULL
to	NULL
couple	NULL
phosphoinositide	NULL
3-kinase	NULL
with	NULL
cytokine	NULL
receptors	NULL
[	NULL
36	NULL
]	NULL
.	NULL

The	NULL
serine	NULL
phosphorylation	NULL
of	NULL
STAT3	NULL
in	NULL
neutrophils	NULL
stimulated	NULL
with	NULL
chemotactic	NULL
factors	NULL
could	NULL
similarly	NULL
have	NULL
a	NULL
regulatory	NULL
role	NULL
in	NULL
protein-protein	NULL
interactions	NULL
,	NULL
although	NULL
this	NULL
obviously	NULL
needs	NULL
further	NULL
study	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
STAT3	NULL
phosphorylation	NULL
on	NULL
Ser-727	NULL
in	NULL
neutrophils	NULL
seems	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
two	NULL
distinct	NULL
pathways	NULL
that	NULL
are	NULL
recruited	NULL
in	NULL
a	NULL
stimulus-specific	NULL
manner	NULL
.	NULL

Chemotactic	NULL
factors	NULL
and	NULL
a	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
operate	NULL
mostly	NULL
or	NULL
exclusively	NULL
through	NULL
the	NULL
ERK	NULL
pathway	NULL
.	NULL

Cytokines	NULL
might	NULL
use	NULL
this	NULL
pathway	NULL
but	NULL
also	NULL
recruit	NULL
an	NULL
additional	NULL
pathway	NULL
not	NULL
involving	NULL
ERKs	NULL
,	NULL
p38	NULL
MAP	NULL
kinase	NULL
or	NULL
an	NULL
H7-sensitive	NULL
kinase	NULL
.	NULL

STAT3	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
clearly	NULL
separable	NULL
from	NULL
serine	NULL
phosphorylation	NULL
,	NULL
i.e	NULL
.	NULL

it	NULL
is	NULL
caused	NULL
by	NULL
cytokines	NULL
but	NULL
not	NULL
by	NULL
chemotactic	NULL
factors	NULL
.	NULL

The	NULL
results	NULL
prompt	NULL
further	NULL
studies	NULL
to	NULL
identify	NULL
the	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
,	NULL
other	NULL
than	NULL
ERK	NULL
s	NULL
,	NULL
that	NULL
phosphorylate	NULL
STAT3	NULL
on	NULL
serine	NULL
as	NULL
well	NULL
as	NULL
to	NULL
clarify	NULL
the	NULL
function	NULL
of	NULL
serine-phosphorylated	NULL
STAT3	NULL
.	NULL

REFERENCES	NULL
Schindler	NULL
,	NULL
C.	NULL
and	NULL
Darnell	NULL
,	NULL
Jr.	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

64	NULL
,	NULL
621-651	NULL
Leaman	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Leung	NULL
,	NULL
S.	NULL
,	NULL
Li	NULL
,	NULL
X.	NULL
and	NULL
Stark	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
FASEB	NULL
J	NULL
.	NULL

10	NULL
,	NULL
1578-1588	NULL
Pellegrini	NULL
,	NULL
S.	NULL
and	NULL
Dusanter-Fourt	NULL
,	NULL
1	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

248	NULL
,	NULL
615-633	NULL
Wen	NULL
,	NULL
Z.	NULL
,	NULL
Zhong	NULL
,	NULL
Z.	NULL
and	NULL
Darnell	NULL
,	NULL
Jr.	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
82	NULL
,	NULL
241-250	NULL
m	NULL
os	NULL
no	NULL
Received	NULL
15	NULL
February	NULL
1999/29	NULL
April	NULL
1999	NULL
;	NULL
accepted	NULL
24	NULL
May	NULL
1999	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
20	NULL
21	NULL
22	NULL
23	NULL
24	NULL
25	NULL
26	NULL
27	NULL
28	NULL
29	NULL
30	NULL
31	NULL
32	NULL
33	NULL
34	NULL
35	NULL
36	NULL
Zhang	NULL
,	NULL
X.	NULL
,	NULL
Blenis	NULL
,	NULL
J.	NULL
,	NULL
Li	NULL
,	NULL
H.-C.	NULL
,	NULL
Schindler	NULL
,	NULL
C.	NULL
and	NULL
Cheng-Kiang	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
1990-1994	NULL
Boulton	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
Zhong	NULL
,	NULL
Z.	NULL
,	NULL
Wen	NULL
,	NULL
Z.	NULL
,	NULL
Darnell	NULL
,	NULL
Jr.	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Stahl	NULL
,	NULL
N.	NULL
and	NULL
Yancopoulos	NULL
,	NULL
G.	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
92	NULL
,	NULL
6915-6919	NULL
Lutticken	NULL
,	NULL
C.	NULL
,	NULL
Coffer	NULL
,	NULL
P.	NULL
,	NULL
Yuan	NULL
,	NULL
J.	NULL
,	NULL
Schwartz	NULL
,	NULL
C.	NULL
,	NULL
Caldenhoven	NULL
,	NULL
E.	NULL
,	NULL
Schindler	NULL
,	NULL
C.	NULL
,	NULL
Kruijer	NULL
,	NULL
W.	NULL
,	NULL
Heinrich	NULL
,	NULL
P.	NULL
C.	NULL
and	NULL
Horn	NULL
,	NULL
F.	NULL
(	NULL
1995	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

360	NULL
,	NULL
137-143	NULL
Ceresa	NULL
,	NULL
B.	NULL
and	NULL
Pessin	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
12121-12124	NULL
Gotoh	NULL
,	NULL
A.	NULL
,	NULL
Takahira	NULL
,	NULL
H.	NULL
,	NULL
Mantel	NULL
,	NULL
C.	NULL
,	NULL
Litz-Jackson	NULL
,	NULL
S.	NULL
,	NULL
Boswell	NULL
,	NULL
H.	NULL
S.	NULL
and	NULL
Broxmeyer	NULL
,	NULL
H.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
Blood	NULL
88	NULL
,	NULL
138-145	NULL
Ng	NULL
,	NULL
J.	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
24542-24549	NULL
Chung	NULL
,	NULL
J.	NULL
,	NULL
Uchida	NULL
,	NULL
E.	NULL
,	NULL
Grammer	NULL
,	NULL
T.	NULL
C.	NULL
and	NULL
Blenis	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
6508-6516	NULL
Frank	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Mahajan	NULL
,	NULL
S.	NULL
and	NULL
Ritz	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

100	NULL
,	NULL
3140-3148	NULL
Stephens	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Lumpkin	NULL
,	NULL
S.	NULL
J.	NULL
and	NULL
Fishman	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273	NULL
,	NULL
31408-31416	NULL
Gerard	NULL
,	NULL
C.	NULL
and	NULL
Gerald	NULL
,	NULL
N.	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
140-145	NULL
Rapoport	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
Abboud	NULL
,	NULL
C.	NULL
N.	NULL
and	NULL
Dipersio	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
Blood	NULL
Rev	NULL
.	NULL

6	NULL
,	NULL
43-57	NULL
Grinstein	NULL
,	NULL
S.	NULL
and	NULL
Furuya	NULL
,	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
18122-18125	NULL
Thompson	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Marshall	NULL
,	NULL
C.	NULL
J.	NULL
and	NULL
Saklatvala	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
9486-9492	NULL
O'Flaherty	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Kuroki	NULL
,	NULL
M.	NULL
,	NULL
Nixon	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
Wijkander	NULL
,	NULL
J.	NULL
,	NULL
Yes	NULL
,	NULL
E.	NULL
,	NULL
Lee	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Smitherman	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
Wykie	NULL
,	NULL
R.	NULL
L.	NULL
and	NULL
Daniel	NULL
,	NULL
L.	NULL
W.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
17821-17828	NULL
Kuroki	NULL
,	NULL
M.	NULL
and	NULL
O'Flaherty	NULL
,	NULL
J.	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

232	NULL
,	NULL
474-477	NULL
Downey	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Butler	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Tapper	NULL
,	NULL
H.	NULL
,	NULL
Fialkow	NULL
,	NULL
H.	NULL
,	NULL
Saltiel	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Rubin	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
and	NULL
Grinstein	NULL
,	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
434-443	NULL
Coffer	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Glijsen	NULL
,	NULL
N.	NULL
,	NULL
M'Rabet	NULL
,	NULL
L.	NULL
,	NULL
Schweizer	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Maikoe	NULL
,	NULL
T.	NULL
,	NULL
Raaijmakers	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
M.	NULL
,	NULL
Lammers	NULL
,	NULL
J.-W.	NULL
and	NULL
Koenderman	NULL
,	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

329	NULL
,	NULL
121-130	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
16483-16486	NULL
Colotta	NULL
,	NULL
F.	NULL
,	NULL
Wang	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Polentarutti	NULL
,	NULL
N.	NULL
and	NULL
Mantovani	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165	NULL
,	NULL
1224-1229	NULL
Itami	NULL
,	NULL
M.	NULL
,	NULL
Kuroki	NULL
,	NULL
T.	NULL
and	NULL
Nose	NULL
,	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

222	NULL
,	NULL
289-292	NULL
Cassatella	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
16	NULL
,	NULL
21-26	NULL
Brizzi	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Aronica	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Rosso	NULL
,	NULL
A.	NULL
,	NULL
Bagnara	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Yarden	NULL
,	NULL
Y.	NULL
and	NULL
Pegoraro	NULL
,	NULL
L.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
3562-3567	NULL
Al-Shami	NULL
,	NULL
A.	NULL
,	NULL
Mahanna	NULL
,	NULL
W.	NULL
and	NULL
Naccache	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273	NULL
,	NULL
1058-1063	NULL
Bovolenta	NULL
,	NULL
C.	NULL
,	NULL
Casperini	NULL
,	NULL
S.	NULL
and	NULL
Cassatella	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

389	NULL
,	NULL
239-242	NULL
Alessi	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Cuenda	NULL
,	NULL
A.	NULL
,	NULL
Cohen	NULL
,	NULL
P.	NULL
,	NULL
Dundley	NULL
,	NULL
D.	NULL
T.	NULL
and	NULL
Saitiel	NULL
,	NULL
A.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
27489-27494	NULL
Hsiao	NULL
,	NULL
K.-M.	NULL
,	NULL
Chou	NULL
,	NULL
S.-Y	NULL
.	NULL

,	NULL
Shih	NULL
,	NULL
S.-J	NULL
.	NULL

and	NULL
Ferrell	NULL
,	NULL
Jr.	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
91	NULL
,	NULL
5480-5484	NULL
Bhat	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Thekkumkara	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Thomas	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Conrad	NULL
,	NULL
K.	NULL
M.	NULL
and	NULL
Baker	NULL
,	NULL
K.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
31443-31449	NULL
Marrero	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Schieffer	NULL
,	NULL
B.	NULL
,	NULL
Paxton	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Heerdt	NULL
,	NULL
L.	NULL
,	NULL
Berk	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
Delafontaine	NULL
,	NULL
P.	NULL
and	NULL
Bernstein	NULL
,	NULL
K.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
375	NULL
,	NULL
247-250	NULL
Bhat	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Abraham	NULL
,	NULL
S.	NULL
T.	NULL
and	NULL
Baker	NULL
,	NULL
K.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
22447-22452	NULL
Wong	NULL
,	NULL
M.	NULL
and	NULL
Fish	NULL
,	NULL
E.	NULL
N.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273	NULL
,	NULL
308-314	NULL
Miyakawa	NULL
,	NULL
Y.	NULL
,	NULL
Oda	NULL
,	NULL
A.	NULL
,	NULL
Druker	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Miyazaki	NULL
,	NULL
H.	NULL
,	NULL
Handa	NULL
,	NULL
M.	NULL
,	NULL
Ohashi	NULL
,	NULL
H.	NULL
and	NULL
Ikeda	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Blood	NULL
87	NULL
,	NULL
439-446	NULL
Pfeffer	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Mullersman	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Pfeffer	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Murti	NULL
,	NULL
A.	NULL
,	NULL
Shi	NULL
,	NULL
W.	NULL
and	NULL
Yang	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
Science	NULL
276	NULL
,	NULL
1418-1420	NULL
©	NULL
1999	NULL
Biochemical	NULL
Society	NULL

